静脈血栓塞栓症（VTE）の市場規模と動向：疫学、疾患管理、パイプライン分析、競合評価、アンメットニーズ、臨床試験戦略、予測（～2032年）

主要7市場（米国・フランス・ドイツ・イタリア・スペイン・英国・日本）の静脈血栓塞栓症（VTE）の市場規模は、2022年の約35億7,000万米ドルから予測期間の終わりまでに46億2,000万米ドルに達し、CAGRで2.6%の成長が予測されています。このわずかな成長は、予測期間中に起こる新規経口抗凝固薬（NOAC）の特許の失効に伴う、ジェネリック医薬品の侵食などに起因します。

当レポートでは、主要7市場の多発性硬化症（MS）市場について調査分析し、収益の予測、パイプライン分析、競合情勢などを提供しています。

目次

第1章 静脈血栓塞栓症（VTE）：エグゼクティブサマリー

• VTE市場は2022年～2032年に最小限の成長となる
• 企業は第XI因子阻害薬の臨床試験開発に注力している
• がんや腎障害の患者に対する最適な治療戦略が求められる
• アベラシマブは予測期間中の売上にほどほどに寄与する
• 医師たちは何を考えるか

第2章 イントロダクション

• 触媒
• 関連レポート
• 今後のレポート

第3章 疾患の概要

• 病因学と病態生理学

第4章 疫学

• 疾患の背景
• 危険因子と併存疾患
• 世界の過去の動向
• 主要7市場の予測手法
• 静脈血栓塞栓症（VTE）の疫学予測（2022年～2032年）
• 論考

第5章 疾病管理

• 診断と治療の概要
• 疾病管理に関するKOLの考察

第6章 競合評価

• 概要

第7章 アンメットニーズと機会の評価

• 概要
• 出血リスクの軽減
• がん患者に対する最適な治療
• 腎障害・腎不全患者に対する最適な治療
• 非経口療法に伴う合併症
• 医師と患者の教育の改善

第8章 研究開発戦略

• 概要
• 臨床試験の設計

第9章 パイプライン評価

• 概要
• 臨床開発中の有望な薬品

第10章 パイプライン評価分析

• 概要
• 競合評価

第11章 現在と将来の企業

• 概要
• 取引決定の動向

第12章 市場見通し

• 世界市場
• 米国
• 欧州5か国
• 日本

第13章 付録

List of Tables

List of Tables

• Table 1: VTE: key metrics in the 7MM
• Table 2: Risk factors and comorbidities for VTE
• Table 3: Treatment guidelines for VTE
• Table 4: VTE market - global drivers and barriers, 2022-32
• Table 5: Key events impacting sales for VTE in the US, 2022-32
• Table 6: VTE market - drivers and barriers in the US, 2022-32
• Table 7: Key events impacting sales for VTE in the 5EU, 2022-32
• Table 8: VTE market - drivers and barriers in the 5EU, 2022-32
• Table 9: Key events impacting sales for VTE in Japan, 2022-32
• Table 10: VTE market - drivers and barriers in Japan, 2022-32
• Table 11: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

List of Figures

• Figure 1: Global sales forecast by country for VTE in 2022 and 2032
• Figure 2: Analysis of the company portfolio gap in venous thromboembolism during the forecast period
• Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of venous thromboembolism during the forecast period
• Figure 4: 7MM, diagnosed incidence of PE, DVT, and VTE, cases per 100,000 population, both sexes, all ages, 2022
• Figure 5: 7MM, sources used to forecast the diagnosed incident cases of PE, DVT, and VTE
• Figure 6: 7MM, sources used to forecast the diagnosed incident cases of DVT by anatomical region
• Figure 7: 7MM, sources used to forecast the diagnosed incident cases of VTE by provoking risk factor
• Figure 8: 7MM, sources used to forecast the diagnosed incident cases of VTE with cancer as a comorbidity
• Figure 9: 7MM, sources used to forecast the diagnosed incident cases of VTE with CKD as a comorbidityu
• Figure 10: 7MM, sources used to forecast the diagnosed VTE attacks
• Figure 11: 7MM, sources used to forecast VTE recurrence after one and 10 years
• Figure 12: 7MM, sources used to forecast the number of hospital discharges that meet medically ill criteria and are at risk of VTE
• Figure 13: 7MM, sources used and not used to forecast the primary total knee replacements and revisions, and hip replacements.
• Figure 14: 7MM, diagnosed incident cases of PE, N, both sexes, all ages, 2022
• Figure 15: 7MM, diagnosed incident cases of DVT, N, both sexes, all ages, 2022
• Figure 16: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2022
• Figure 17: 7MM, diagnosed incident cases of VTE by age, N, both sexes, all ages, 2022
• Figure 18: 7MM, diagnosed incident cases of VTE by sex, N, both sexes, all ages, 2022
• Figure 19: 7MM, diagnosed incident cases of DVT by anatomical region, N, all ages, 2022
• Figure 20: 7MM, diagnosed incident cases of VTE by provoking risk factor, N, both sexes, all ages, 2022
• Figure 21: 7MM, first-time recurrent cases of VTE, N, both sexes, all ages, 2022
• Figure 22: 7MM, diagnosed incident cases of VTE with cancer as a comorbidity, N, both sexes, all ages, 2022
• Figure 23: 7MM, diagnosed incident cases of VTE with CKD as a comorbidity, N, both sexes, 2022 and 2032
• Figure 24: 7MM, diagnosed VTE attacks, N, both sexes, all ages, 2022 and 2032
• Figure 25: 7MM, number of medically ill hospital discharges at risk for VTE, N, both sexes, ≥40 years, 2022
• Figure 26: 7MM, total number of knee replacements, N, both sexes, ≥15 years, 2022 and 2032
• Figure 27: 7MM, total number of hip replacements, N, both sexes, ≥15 years, 2022 and 2032
• Figure 28: Treatment algotrithm for VTE
• Figure 29: Unmet needs and opportunities in VTE
• Figure 30: Overview of the development pipeline in VTE
• Figure 31: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for VTE in the 7MM during the forecast period
• Figure 32: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of VTE during the forecast period
• Figure 33: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC: NOACs
• Figure 34: Analysis of the company portfolio gap in VTE during the forecast period
• Figure 35: Deal-making trends, number of deals, 2018-22
• Figure 36: Deal-making trends, value of deals, 2018-22
• Figure 37: 7MM sales forecast by country for VTE in 2022 and 2032
• Figure 38: Sales forecast by class for VTE treatment in the US in 2022 and 2032
• Figure 39: Sales forecast by class for VTE primary prophylaxis in the US in 2022 and 2032
• Figure 40: Sales forecast by country for VTE treatment and primary prophylaxis in the 5EU in 2022 and 2032
• Figure 41: Sales forecast by class for VTE treatment and primary prophylaxis in the 5EU in 2022 and 2032
• Figure 42: Sales forecast by class for VTE treatment in Japan in 2022 and 2032
• Figure 43: Sales forecast by class for VTE primary prophylaxis in Japan in 2022 and 2032

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Venous Thromboembolism (VTE) market through 2032.

According to GlobalData estimates, 2022 base year sales within the VTE market are approximately $3.57 billion across the 7MM detailed in this report. The US is the most significant contributor to that revenue, accounting for 80.8% of sales. This can be attributed to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan. GlobalData estimates that the VTE market will grow at a compound annual growth rate (CAGR) of 2.6% to reach $4.62 billion by the end of the forecast period. This minimal growth is due to the generic erosion that will occur as patents for novel oral anticoagulants (NOACs) expire throughout the forecast period. Furthermore, although there is one late-stage pipeline therapy that is expected to launch in the US and 5EU during the forecast period, the drug will only capture a small share of the market due to its high cost, subcutaneous method of administration, long half-life, and lack of strong clinical trial data.

Report deliverables include a Pdf and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2022-2032.

• 2022 base year sales within the VTE market are approximately $3.57 billion across the 7MM detailed in this report. GlobalData estimates that the VTE market will grow at a compound annual growth rate (CAGR) of 2.6% to reach $4.62 billion by the end of the forecast period.
• This minimal growth is due to the generic erosion that will occur as patents for novel oral anticoagulants (NOACs) expire throughout the forecast period as well as only one late-stage pipeline therapy that will only capture a small share of the market due to its high cost, subcutaneous method of administration, and lack of strong clinical trial data.

Scope

• Overview of VTE, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized VTE therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the VTE market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for VTE treatment and prophylaxis. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Venous Thromboembolism: Executive Summary

• 1.1 The VTE market will experience minimal growth between 2022 and 2032
• 1.2 Companies are focusing clinical trial development on factor XI inhibitors
• 1.3 Optimal treatment strategies for patients with cancer or renal impairment are needed
• 1.4 Abelacimab to contribute moderately to sales during the forecast period
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology
• 4.5 Epidemiological forecast for venous thromboembolism (VTE) (2022-32)
• 4.6 Discussion

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 Key opinion leader insights on disease management

6 Competitive Assessment

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Mitigating bleeding risk
• 7.3 Optimal treatment for cancer patients
• 7.4 Optimal treatment for patients with renal impairment and renal failure
• 7.5 Complications associated with parenteral therapies
• 7.6 Improved education among physicians and patients

8 R&D Strategies

• 8.1 Overview
• 8.2 Clinical trials design

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
• 12.2 US
• 12.3 5EU
• 12.4 Japan

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
• 13.4 Primary research - key opinion leaders interviewed for this report
• 13.5 Primary research - prescriber survey
• 13.6 About the Authors
• Contact Us